Dr. Sonya Reid introduces the program by outlining the objectives of the discussion, which focus on the expanding role of genomic testing in the management of early-stage HR-positive, HER2-negative breast cancer.
Back
Optimizing Treatment Decision-Making in Early-Stage Breast Cancer: Integrating Genomic Testing into Clinical Practice
This OncLive® Insights program features Dr. Sonya Reid and Dr. Allison DiPasquale discussing the evolving role of genomic testing in early-stage hormone receptor-positive, HER2-negative breast cancer and its integration into contemporary clinical practice. The faculty examine how multigene assays complement traditional clinicopathologic factors to support individualized treatment planning, improve risk stratification, and guide adjuvant therapy decisions. The discussion reviews the clinical impact of landmark studies, including TAILORx and RxPONDER, and explores how these data have influenced treatment recommendations for node-negative and node-positive disease. Dr. Reid and Dr. DiPasquale also share practical perspectives on incorporating genomic testing into multidisciplinary care, interpreting recurrence scores, selecting and applying available genomic assays in different clinical scenarios, communicating results with patients, and balancing evidence-based recommendations with real-world clinical decision-making. The program concludes with key insights into the future of precision medicine and ongoing research aimed at further personalizing treatment for patients with early-stage breast cancer.
Optimizing Treatment Decision-Making in Early-Stage Breast Cancer: Integrating Genomic Testing into Clinical Practice
Episodes
All
All
Dr. Sonya Reid invites Dr. Allison DiPasquale to discuss how genomic testing is incorporated into the clinical workflow for patients with early-stage HR-positive, HER2-negative breast cancer.
Dr. Sonya Reid and Dr. Allison DiPasquale discuss how clinical practice guidelines have influenced the use of genomic testing in the management of early-stage HR-positive, HER2-negative breast cancer.
Dr. Allison DiPasquale and Dr. Sonya Reid discuss the advantages and limitations of performing genomic testing on biopsy specimens versus final surgical pathology in early-stage HR-positive, HER2-negative breast cancer.
Dr. Allison DiPasquale invites Dr. Sonya Reid to discuss the clinical impact of the landmark TAILORx trial on the management of early-stage HR-positive, HER2-negative, node-negative breast cancer.
Dr. Allison DiPasquale and Dr. Sonya Reid discuss how findings from the RxPONDER trial have influenced treatment decision-making for patients with early-stage HR-positive, HER2-negative, node-positive breast cancer.
Dr. Sonya Reid asks Dr. Allison DiPasquale how recurrence scores influence treatment recommendations and patient discussions in early-stage HR-positive, HER2-negative breast cancer.
Dr. Sonya Reid and Dr. Allison DiPasquale discuss factors that influence the selection and application of genomic assays in the management of early-stage HR-positive, HER2-negative breast cancer.
Dr. Allison DiPasquale asks Dr. Sonya Reid how longer-term follow-up from landmark studies has influenced confidence in the use of genomic assays for early-stage HR-positive, HER2-negative breast cancer.
Dr. Sonya Reid and Dr. Allison DiPasquale discuss how treatment planning for early-stage HR-positive, HER2-negative breast cancer extends beyond genomic assay results alone by integrating clinicopathologic features and patient-specific factors.
Dr. Allison DiPasquale and Dr. Sonya Reid discuss how multidisciplinary collaboration supports the integration of genomic testing into the management of early-stage HR-positive, HER2-negative breast cancer.
Dr. Allison DiPasquale and Dr. Sonya Reid conclude the discussion by highlighting the future of personalized care in early-stage HR-positive, HER2-negative breast cancer and the evolving role of genomic testing.
Advertisement
Advertisement
Trending on OncLive
1
ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma
2
Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma
3
The OncFive: Top Oncology Articles for the Week of 8/16
4
ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC
5